Physician profile
Roussel Clement
NPI 1710977913
$6,084.45
in general payments reported to CMS, 2019-2025
40 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $525 · 2021: $1,204 · 2022: $1,113 · 2023: $1,089 · 2024: $627 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.07 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $748.52 | 2021-2025 | |
| Abbvie INC. | $737.65 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Daiichi Sankyo INC. | $733.97 | 2019-2023 | Enhertu, Injectafer |
| Pfizer INC. | $616.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $588.06 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Indivior INC. | $376.09 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.06 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $323.80 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $203.37 | 2019-2022 | |
| Smith+Nephew, INC. | $199.20 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home |
| Amarin Pharma, INC. | $111.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $108.59 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $100.65 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $89.21 | 2021-2022 | |
| Dexcom, INC. | $76.69 | 2021-2025 | Dexcom G6 Transmitter |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $74.43 | 2020-2024 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $73.25 | 2021 | |
| Biogen, INC. | $59.28 | 2020-2021 | |
| Allergan, INC. | $55.39 | 2019-2020 | |
| Kci USA, INC. | $42.17 | 2021 | |
| Orexo US, INC. | $37.84 | 2019-2020 | |
| Eisai INC. | $35.99 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $34.70 | 2023 | Quviviq |
| Convatec INC. | $32.28 | 2023 | |
| Ironwood Pharmaceuticals, INC | $30.40 | 2019 | |
| Medtronic, INC. | $24.59 | 2023 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $24.56 | 2023 | Keveyis |
| Abbott Laboratories | $21.73 | 2022 | |
| Braeburn INC. | $21.46 | 2023 | Brixadi |
| Kowa Pharmaceuticals America, INC. | $20.08 | 2023 | Seglentis |
| Solventum Corporation | $19.55 | 2024 | Prevena, Activ.A.C. |
| Janssen Pharmaceuticals, INC | $17.40 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.80 | 2021 | |
| Melinta Therapeutics, LLC | $14.61 | 2019 | |
| Amgen INC. | $14.00 | 2025 | Otezla, Repatha |
| Philips North America LLC | $13.67 | 2022 | |
| Glaxosmithkline, LLC. | $13.19 | 2023 | Arexvy |
| Fidia Pharma USA INC. | $12.85 | 2023 | Triluron, Hymovis |
| Ibsa Pharma INC. | $12.27 | 2020 | |
| Global Blood Therapeutics, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roussel Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.